Health nut
31 August 2020

The $348 bln Swiss giant is buying allergy treatment firm Aimmune. It makes the first approved product for food allergies to the nut. The ingredient isn’t prominent in its portfolio, so CEO Mark Schneider will essentially get a lift from making rivals’ products more accessible.